MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

June 11, 2024

Study Completion Date

June 11, 2024

Conditions

Adenocarcinoma of the ColonAdenocarcinoma of the Rectum

Interventions

DRUG

Cetuximab

Patients in Arm A will receive FOLFIRI +cetuximab.

OTHER

FOLFIRI

Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)

Trial Locations (4)

Universitätsklinikum Knappschaftskrankenhaus, Bochum

Onkologisches Zentrum (Dachau II), Dachau

Kliniken-Essen-Mitte Evang. Huyssens-Stiftung, Essen

Evangelisches Krankenhaus Hamm, Hamm

All Listed Sponsors

lead

TheraOp

OTHER

NCT04554836 - MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab | Biotech Hunter | Biotech Hunter